Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 850 participants.

Also called NCT04462536

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 850 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04462536
Other papers using this trial's data
  • Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial Lancet (London, England), 2025-02-15 DOI, PubMed 39955119

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Germany, Italy, Netherlands, Norway, Singapore, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04462536. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-06 (actual); primary completion 2023-08-31 (actual). Results posted on 2025-06-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
Acronym
ESCAPE-NEXT
Condition
Stroke, Acute
Intervention (Drug)
Placebo
Intervention (Drug)
Nerinetide
Lead sponsor
NoNO Inc. (class: industry)
Collaborator
University of Calgary (class: other)

Record details

Record id
cardio:ct-nct04462536
Content hash
d7d484057c23b4d33c1b12cbe0dc52b64f462fb78df632e2206a55e2dd3accde